Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
Holding ARDX?
Track your performance easily
ARDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.34 - $10.13
Previous Close$5.22
Volume2.13M
Average Volume (3M)4.00M
Market Cap
$1.24B
Enterprise Value$1.15B
Total Cash (Recent Filing)$190.40M
Total Debt (Recent Filing)$104.49M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 05, 2025EPS Estimate
<$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding236,854,270
10 Day Avg. Volume3,272,871
30 Day Avg. Volume4,003,041
Standard Deviation0.22
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)7.79
Price to Sales (P/S)4.93
Price to Cash Flow (P/CF)619.30
P/FCF Ratio852.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.57
Enterprise Value/Gross Profit10.79
Enterprise Value/Ebitda-20.97
Forecast
1Y Price Target
$10.25Price Target Upside96.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Ardelyx News
PremiumCompany Announcements
Ardelyx Appoints Joseph Reilly as Principal Accounting Officer
PremiumCompany Announcements
Ardelyx Reports Robust Q3 2024 Revenue Growth
Bulls Say, Bears Say
Bulls Say
Product PotentialFocus should shift to Ibsrela’s steady path to becoming a $1B product, with tangible tailwinds from its fully deployed and expanded sales force.
Revenue GrowthArdelyx reported a 3Q24 total revenues top line beat of ~$98M (~34% increase Q/Q), which was ~13%/~17% above FactSet consensus/our estimates, exhibiting strong growth for both Ibsrela in IBS-C and, once again, their newer launched product Xphozah for hyperphosphatemia.
Sales PerformanceARDX delivered another exceptional quarter with XPHOZAH sales of $51.5M, demonstrating robust demand even in the early innings of the launch.
Bears Say
Legal ChallengesThe lawsuit filed by Ardelyx to prevent CMS from including XPHOZAH in the bundle was dismissed by the District Court.
Reimbursement UncertaintyUncertainty surrounds XPHOZAH's reimbursement status for Medicare patients, which affects a large portion of its addressable market.
Stock DowngradeThe analyst downgrades ARDX shares to Neutral due to the recent court decision and increased corporate risk and uncertainty.
---
Ownership Overview
2.45% Insiders
19.40% Mutual Funds
9.92% Other Institutional Investors
54.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $4.34 and its highest was $10.13 in the past 12 months.
What is Ardelyx’s market cap?
Currently, no data Available
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Mar 05, 2025 which is in 81 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Oct 31, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.049.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is <$0.01.
How many shares outstanding does Ardelyx have?
Ardelyx has 236,854,260 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of $0 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went up 3.748%.
Which hedge fund is a major shareholder of Ardelyx?
Among the largest hedge funds holding Ardelyx’s share is Oracle Investment Management Inc. It holds Ardelyx’s shares valued at 9M.
---
Ardelyx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.25 (96.36% Upside)
$10.25 (96.36% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 95%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 86.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $422.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.74%
12-Months-Change
Fundamentals
Return on Equity
-41.54%
Trailing 12-Months
Asset Growth
27.12%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
ARDX Earnings Call
Q3 2024
0:00 / 0:00
---
ARDX Stock 12 Month Forecast
Average Price Target
$10.25
▲(96.36% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+59.27%
reiterated a buy rating last month
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +59.27% per trade.
---